Tead2-KO Mouse
一般名
Tead2-KO
製品ID
S-KO-05205
背景情報
C57BL/6NCya
系統ID
KOCMP-21677-Tead2-B6N-VA
状況
このマウス系統を論文で使用する場合は、「Tead2-KO Mouse（カタログ番号S-KO-05205）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Tead2-KO
系統ID
KOCMP-21677-Tead2-B6N-VA
遺伝子名
製品ID
S-KO-05205
遺伝子別名
ETF, Etdf, TEF4, TEF-4, ETEF-1, TEAD-2
遺伝子別名
C57BL/6NCya
NCBI ID
修正
Conventional knockout
染色体
Chr 7
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000033060
NCBIトランスクリプトID
NM_011565
ターゲット領域
Exon 3~6
有効領域の大きさ
~2.6 kb
遺伝子研究の概要
TEAD2, a member of the TEA domain transcription factor family, is involved in crucial biological processes. It participates in the Hippo signaling pathway, which is vital for tissue growth, organ size control, and cell fate determination [1,4,5,7,9]. TEAD2 also plays a role in maintaining ground-state pluripotency in mouse embryonic stem cells, facilitating the transition between different culture conditions by mediating chromatin looping and enhancer-promoter interactions [2].
In disease-related studies, TEAD2 has been implicated in multiple cancers. In hepatocellular carcinoma (HCC), deletion of TAZ, which acts with TEAD2, consistently decreased HCC growth and mortality, while overexpression of activated TAZ triggered HCC. TAZ-and MET/CTNNB1-S45Y-driven HCC required the expression of TEAD2, and TEAD2 had a profound effect on patient survival [1]. Additionally, TEAD2 promoted HCC development and sorafenib resistance by transcriptionally activating TAK1 [4]. In pancreatic ductal adenocarcinoma, a TEAD2-driven endothelial-like program was associated with basal-like differentiation and metastasis, and genetic and pharmacologic inhibitions of TEAD2 impaired cancer progression [3]. In melanoma, vemurafenib resistance upregulated STIM1 through an EGF/EGFR-YAP1/TEAD2 signaling axis [6]. In colorectal cancer, PHF5A promoted cancer progression by alternative splicing of TEAD2 to activate YAP signaling [8].
In conclusion, TEAD2 is essential for maintaining pluripotency and plays significant roles in cancer development and progression, especially in HCC, pancreatic cancer, melanoma, and colorectal cancer. The use of gene knockout or conditional knockout mouse models in these studies has been crucial in revealing the function of TEAD2 in these biological processes and disease conditions, providing potential therapeutic targets for these cancers.
References:
1. Saito, Yoshinobu, Yin, Dingzi, Kubota, Naoto, Wangensteen, Kirk J, Schwabe, Robert F. 2023. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23. In Gastroenterology, 164, 1279-1292. doi:10.1053/j.gastro.2023.02.043. https://pubmed.ncbi.nlm.nih.gov/36894036/
2. Guo, Rong, Dong, Xiaotao, Chen, Feng, Hu, Gongcheng, Yao, Hongjie. 2024. TEAD2 initiates ground-state pluripotency by mediating chromatin looping. In The EMBO journal, 43, 1965-1989. doi:10.1038/s44318-024-00086-5. https://pubmed.ncbi.nlm.nih.gov/38605224/
3. Yoo, Hye-Been, Moon, Jin Woo, Kim, Hwa-Ryeon, Kim, Mi-Young, Roe, Jae-Seok. 2023. A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer. In Gastroenterology, 165, 133-148.e17. doi:10.1053/j.gastro.2023.02.049. https://pubmed.ncbi.nlm.nih.gov/36907523/
4. Zhang, Yahui, Ren, Yidan, Dong, Guoying, Wang, Yunshan, Zhao, Wei. . TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation. In Molecular cancer research : MCR, 22, 1102-1116. doi:10.1158/1541-7786.MCR-24-0060. https://pubmed.ncbi.nlm.nih.gov/39106149/
5. Joo, Jong Seok, Cho, Sang Yeon, Rou, Woo Sun, Eun, Hyuk Soo, Lee, Byung Seok. 2020. TEAD2 as a novel prognostic factor for hepatocellular carcinoma. In Oncology reports, 43, 1785-1796. doi:10.3892/or.2020.7578. https://pubmed.ncbi.nlm.nih.gov/32323824/
6. Bai, Weiyu, Yan, Chenghao, Yang, Yichen, Sun, Yan, Sun, Jianwei. 2024. EGF/EGFR-YAP1/TEAD2 signaling upregulates STIM1 in vemurafenib resistant melanoma cells. In The FEBS journal, 291, 4969-4983. doi:10.1111/febs.17272. https://pubmed.ncbi.nlm.nih.gov/39298503/
7. Park, Sujin, Mossmann, Dirk, Chen, Qian, Heim, Markus H, Hall, Michael N. . Transcription factors TEAD2 and E2A globally repress acetyl-CoA synthesis to promote tumorigenesis. In Molecular cell, 82, 4246-4261.e11. doi:10.1016/j.molcel.2022.10.027. https://pubmed.ncbi.nlm.nih.gov/36400009/
8. Chang, Yue, Zhao, Yulu, Wang, Liya, Chu, Xiaoyuan, Chen, Cheng. 2021. PHF5A promotes colorectal cancerprogression by alternative splicing of TEAD2. In Molecular therapy. Nucleic acids, 26, 1215-1227. doi:10.1016/j.omtn.2021.10.025. https://pubmed.ncbi.nlm.nih.gov/34853721/
9. Alder, Olivia, Cullum, Rebecca, Lee, Sam, Marra, Marco A, Hoodless, Pamela A. 2014. Hippo signaling influences HNF4A and FOXA2 enhancer switching during hepatocyte differentiation. In Cell reports, 9, 261-271. doi:10.1016/j.celrep.2014.08.046. https://pubmed.ncbi.nlm.nih.gov/25263553/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。